Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
antineoplastic agent |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XC14
|
| gptkbp:brand |
gptkb:Kadcyla
|
| gptkbp:CASNumber |
1018448-65-1
|
| gptkbp:chemicalClass |
gptkb:monoclonal_antibody
|
| gptkbp:contains |
gptkb:trastuzumab
gptkb:DM1 |
| gptkbp:developedBy |
gptkb:Genentech
gptkb:Roche |
| https://www.w3.org/2000/01/rdf-schema#label |
ado-trastuzumab emtansine
|
| gptkbp:indication |
metastatic breast cancer
early breast cancer (adjuvant) |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
delivers cytotoxic agent to cancer cells
targets HER2 receptor |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
fatigue thrombocytopenia liver toxicity cardiotoxicity |
| gptkbp:target |
gptkb:HER2_protein
|
| gptkbp:UNII |
P8I9DV1DLW
|
| gptkbp:usedFor |
gptkb:HER2-positive_breast_cancer
|
| gptkbp:bfsParent |
gptkb:Kadcyla
|
| gptkbp:bfsLayer |
6
|